Advanced in Lung Adenocarcinoma

Dr. Shahed N. Badiyan

Radiation Oncology
University Of Texas Southwestern Medical Center At Dallas
2280 Inwood Rd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
16 Years of Experience
Advanced in Lung Adenocarcinoma
University Of Texas Southwestern Medical Center At Dallas
2280 Inwood Rd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shahed Badiyan is a Radiation Oncologist in Dallas, Texas. Dr. Badiyan has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

His clinical research consists of co-authoring 110 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lung Adenocarcinoma.

Graduate Year
2009
Specialties
Radiation Oncology
Licenses
Radiology in TX
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
2280 Inwood Rd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Recruiting
Publish Date: January 22, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
Enrollment Status: Terminated
Publish Date: September 29, 2025
Intervention Type: Radiation, Device
Study Phase: Not Applicable
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological, Procedure, Radiation
Study Drug: Durvalumab
Study Phase: Phase 1
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Radiation
Study Phase: Phase 3
PROactive Evaluation of Function to Avoid CardioToxicity
PROactive Evaluation of Function to Avoid CardioToxicity
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Device
Study Phase: Phase 2
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Carboplatin, Paclitaxel
Study Phase: Phase 1
Non-Operative Management and Early Response Assessment in Rectal Cancer
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug, Radiation
Study Phase: Not Applicable
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer
A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2025
Intervention Type: Radiation, Other
Study Phase: Not Applicable
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Device, Biological, Radiation
Study Drugs: Paclitaxel, Carboplatin AUC, Durvalumab
Study Phase: Phase 2
A Pilot Trial of Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
A Pilot Trial of Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: January 25, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Other
Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma
Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma
Enrollment Status: Terminated
Publish Date: November 04, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging
Enrollment Status: Completed
Publish Date: August 25, 2021
Intervention Type: Other
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
View 17 Less Clinical Trials

110 Total Publications

Expanding SCINTIX Biology-Guided Radiotherapy Beyond Lung and Bone: A Planning Feasibility and Dosimetric Study on the RefleXion X1 System.
Expanding SCINTIX Biology-Guided Radiotherapy Beyond Lung and Bone: A Planning Feasibility and Dosimetric Study on the RefleXion X1 System.
Journal: Technology in cancer research & treatment
Published: August 11, 2025
Similar Doctors
Advanced in Lung Adenocarcinoma
Dr. Arve W. Gillette
Radiation Oncology | Oncology
Advanced in Lung Adenocarcinoma
Dr. Arve W. Gillette
Radiation Oncology | Oncology

Texas Oncology PA

1441 N Beckley Ave, Suite 101, 
Dallas, TX 
 (4.0 miles away)
214-943-9911
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Arve Gillette is a Radiation Oncologist and an Oncologist in Dallas, Texas. Dr. Gillette is rated as an Advanced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Gillette is currently accepting new patients.

Advanced in Lung Adenocarcinoma
Dr. Juan Godinez
Radiation Oncology
Advanced in Lung Adenocarcinoma
Dr. Juan Godinez
Radiation Oncology
2010 Ben Merritt Dr Unit A, 
Decatur, TX 
 (50.3 miles away)
940-626-2300
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Juan Godinez is a Radiation Oncologist in Decatur, Texas. Dr. Godinez is rated as an Advanced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Prostate Cancer, Familial Prostate Cancer, and Small Cell Lung Cancer (SCLC). Dr. Godinez is currently accepting new patients.

Advanced in Lung Adenocarcinoma
Dr. Gary S. Young
Radiation Oncology
Advanced in Lung Adenocarcinoma
Dr. Gary S. Young
Radiation Oncology

Acclaim Physician Group Inc

1350 S Main St, Suite 1600, 
Fort Worth, TX 
 (28.9 miles away)
817-702-9701
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Young is a Radiation Oncologist in Fort Worth, Texas. Dr. Young is rated as an Advanced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Lung Adenocarcinoma. Dr. Young is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Badiyan's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile